TY - JOUR
AU - Vale, Claire L.
AU - Godolphin, Peter J.
AU - Fisher, David J.
AU - Horby, Peter W.
AU - Kosiborod, Mikhail N.
AU - Hochman, Judith S
AU - Webster, Katie E.
AU - Higgins, Julian P. T.
AU - Althouse, Andrew D.
AU - Berwanger, Otavio
AU - Furtado, Remo H M
AU - Gasparyan, Samvel B.
AU - Haynes, Richard
AU - Koch, Gary G
AU - Landray, Martin
AU - Leifer, Eric S
AU - Marshall, John C.
AU - Murthy, Srinivas
AU - Neal, Matthew D.
AU - Staplin, Natalie
AU - Diaz, Janet V.
AU - Sterne, Jonathan A.C.
AU - Shankar-Hari, Manu
PY - 2024
DA - September
TI - Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials
JO - The Lancet Diabetes & Endocrinology
DO - https://doi.org/10.1016/S2213-8587(24)00219-5
AB - Sodium glucose co-transporter-2 inhibitors (SGLT2i) have been proposed as a potential treatment for 3 adults hospitalised with COVID-19, due to their potential anti-inflammatory and endothelial protective 4 effects. To-date published evidence from randomised control trials (RCTs) does not provide evidence 5 of benefit. We aimed to estimate the effect of oral administration of SGLT2i compared with usual care 6 or placebo in adults hospitalised with COVID-19.
PB - Elsevier
UR - https://www.research.ed.ac.uk/en/publications/34f549ac-523a-4285-9aa8-74e5a9b68e97
KW - Coronavirus (COVID-19)
KW - Hospital care
ER